Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- RGNX -18.5%, (provides guidance with 2017 corporate update; had more than $175 mln in cash and equivalents to end the year; FY18 cash burn of $85-95 mln), FRAN -18%, (Francesca's lowers Q4 revenue guidance following disappointing holiday performance), OMED -7%, (CEO Paul J. Hastings resigns to pursue new career opportunities, effective January 1st, 2018; co also provides 2018 outlook), PSMT -6.7%, CALM -4.8%, BKS -3.1%, (Barnes & Noble reports total holiday sales -6.4% y/y to $953 mln; expects FY18 comps to decline in mid-single digits and EBITDA of $140 -160 mln)
Other news:
- OHRP -77.7% (reports topline data from the MAKO study which did not meet its primary efficacy endpoint)
- RGNX -17.6% (provides guidance with 2017 corporate update; had more than $175 mln in cash and equivalents to end the year; FY18 cash burn of $85-95 mln), NOVN -10.4% (commences common stock offering)
- SCYX -7.4% (thinly traded; provides a corporate update; Path forward established for iv program of SCY-078, with clinical trials to initiate in Q3 of 2018 with an improved IV formulation)
- HTGM -7.2% (after surging 75% higher)
- AVXS -4.5% (to submit information requested by FDA to the IND on an on-going basis; plans to request a pre-BLA meeting in Q2 2018 )
- OKE -3.5% (ONEOK to invest approximately $1.4 billion to construct a new pipeline, and related infrastructure, to transport natural gas liquids from the Rocky Mountain region to the company's existing Mid-Continent NGL facilities; launches 19 mln share common stock offering)
- AUPH -3% (filed preliminary short form base shelf prospectus to replace prior expired prospectus/corresponding shelf registration statement ), .
Analyst comments:
- TVPT -1.4% (downgraded to Underperform at Evercore ISI)
- NOK -0.8% (downgraded to Neutral at Credit Suisse)